The China Food and Drug Administration has approved GSK's application for the market authorization of Debroximab injection.

Recently, the National Medical Products Administration approved the listing of Democizumab injection by GlaxoSmithKline Trading Services Limited. This variety is used for the maintenance treatment of severe eosinophilic granulomatosis with polyangiitis in adults and adolescents aged 12 and above. The listing of this variety provides new treatment options for relevant patients.